Ratings Nutex Health Inc.

Equities

Real-time Estimate Cboe BZX Other stock markets 09:03:30 09/05/2024 pm IST			5-day change	1st Jan Change
0.67 ^USD	+3.55%		+6.77%	-76.04%

10:21am	Earnings Flash (NUTX) NUTEX HEALTH Posts Q1 Revenue $67.5M	MT
01:13am	Nutex Health Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach -100% by 2026.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Over the past four months, analysts' average price target has been revised downwards significantly.

	1st Jan change	Capi.	ESG Refinitiv
NUTEX HEALTH INC.	-76.04%	32.07M	-
HCA HEALTHCARE, INC.	+17.12%	81.04B	C+
CVS HEALTH CORPORATION	-30.13%	68.93B	B-
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+9.65%	29.59B	C+
FRESENIUS SE & CO. KGAA	-0.07%	17.24B	A-
LABORATORY CORPORATION OF AMERICA HOLDINGS	-10.96%	16.99B	B
QUEST DIAGNOSTICS INCORPORATED	-0.67%	15.12B	A-
REDE D'OR SÃO LUIZ S.A.	+5.01%	13.09B	B-
TENET HEALTHCARE CORPORATION	+66.24%	12B	C+
EUROFINS SCIENTIFIC SE	-2.88%	11.94B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality